Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...

Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.

Along with the annual flu vaccine, the new COVID-19 vaccine formulation is now widely available in Minnesota. It comes at a ...

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...

Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...

Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines. Read more about PFE stock here.

Currently, the KP.3 and KP.3.1.1 FLiRT variants, derivatives of KP.1 and KP.2, are the most prevalent in Canada and the ...

Free COVID tests are officially back. With COVID-19 cases on the rise, and reports that the new XEC variant is now in half of ...

Pfizer-BioNTech's updated vaccine to protect against a recently circulating variant of COVID-19 is authorized, Health Canada ...

The mRNA vaccine, called Comirnaty, targets the KP.2 subvariant of Omicron, replacing the previous version which targeted the ...